# A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis

> **NCT00287118** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 189 (actual)

## Conditions studied

- Candidates for Systemic Therapy for Psoriasis
- Psoriasis

## Interventions

- **DRUG:** Efalizumab

## Key facts

- **NCT ID:** NCT00287118
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10-27
- **Primary completion:** 2006-05-30
- **Final completion:** 2006-05-30
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2018-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00287118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00287118, "A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00287118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*